Venkat Ram Peddi, MD
Internal Medicine · Fremont
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 8
- Since medical school
- 40 years
- Graduated 1986
Offices
8 locations · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Looking this up.
Hospitals listed: California Pacific Medical Center- Van Ness Campus · Mills-Peninsula Medical Center · Sutter Delta Medical Center · Sutter Medical Center, Sacramento · Sutter Roseville Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Peddi’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence C51237 · Current
Licensed to practise in California · since 2003 · expires 2027-04-30 · Osmania University, Gandhi Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Internal Medicine - Nephrology
Hospitals they work in
5 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- California Pacific Medical Center- Van Ness CampusSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.224, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.325, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.373, Oct 2024 – Sep 2025
- Peninsula Medical CenterBurlingame, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.139, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.242, Oct 2024 – Sep 2025
- Sutter Delta Medical CenterAntioch, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 2 of 5 · 60% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.173, Oct 2024 – Sep 2025
- Sutter Medical Center, SacramentoSacramento, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 79% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 13.9 (12 to 15.9) · 992 cases, Jan 2024 – Dec 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.066, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.335, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.215, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.46, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.253, Oct 2024 – Sep 2025
- Sutter Roseville Medical CenterRoseville, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 79% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Pressure ulcer rate: 0.08 (0 to 0.56) · 12,400 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.069, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.262, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.128, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.357, Oct 2024 – Sep 2025
See every measure and the patient survey for California Pacific Medical Center- Van Ness Campus
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 0 better, 8 the same, 2 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.224 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.325 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.373 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.14 (0.3 to 1.97) · 2,271 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.81 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 192.86 (151.51 to 234.22) · 140 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 10.3 · 60 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.5 · 143 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.8 · 356 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.3 · 259 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 173 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.1 · 2,316 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.31 (0.12 to 0.49) · 6,430 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.09 to 0.47) · 7,168 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.3 (1.5 to 5.09) · 2,196 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.47 (1.21 to 3.74) · 925 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.63 (1.37 to 3.88) · 1,954 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.13 (6.06 to 14.2) · 1,112 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.26 (4.67 to 9.85) · 1,084 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.67 (0.31 to 3.03) · 832 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.33 (0 to 0.85) · 5,406 cases | No different | Jul 2022 – Jun 2024 |
| MRSA BacteremiaInfections | 0.443 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.717 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 200 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.3 · 449 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 18.2 · 187 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 8.7 · 418 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 7.1 · 260 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19.2 · 293 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (3.6 to 7.6) · 157 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.2 (7.7 to 13.5) · 157 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 11 · 33 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.2 · 66 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.5 (9.4 to 16.7) · 551 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.3) · 219 cases | No different | Jan 2024 – Dec 2024 |
What patients said (478 patients answered, 20% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 74% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 70% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for Peninsula Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.139 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.242 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.21 (0.27 to 2.15) · 1,258 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.51 to 1.1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 155.44 (112.67 to 198.21) · 90 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.5 · 32 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 82 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 188 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9 · 473 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.8 · 342 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.4 · 485 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 3,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.4) · 6,904 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,052 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.41 (1.43 to 5.39) · 1,695 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.72 (0.17 to 3.28) · 665 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,545 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.1 (1.3 to 12.9) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.96 (2.63 to 9.29) · 653 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.08) · 418 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.14 (0 to 0.78) · 5,539 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 192 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.215 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.263 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.74 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 300 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19 · 702 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 1.2 · 207 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13.6 · 531 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 24.3 · 343 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 449 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.5 (2.8 to 7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.6 (6.7 to 13.7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 189 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11 · 45 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 117 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (9.7 to 17.2) · 584 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 764 cases | No different | Jan 2024 – Dec 2024 |
What patients said (523 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Sutter Delta Medical Center
Behind the star rating — Deaths: 0 better, 7 the same, 0 worse of 7 measures. Safety: 1 better, 5 the same, 0 worse of 6 measures. Readmissions: 0 better, 5 the same, 2 worse of 7 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.173 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.98 (0 to 2.03) · 561 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.88 (0.47 to 1.29) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 176.46 (114.75 to 238.17) · 31 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.5 · 113 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12 · 100 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.3 · 260 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.2 · 259 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 12.5 · 56 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.8 · 1,274 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.02 to 0.46) · 3,285 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.24 (0.04 to 0.45) · 3,374 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.47 (1.02 to 5.93) · 364 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.16 (0.49 to 3.83) · 323 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.63 (0 to 18.4) · 26 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.71 (0.2 to 3.22) · 81 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.24 (0 to 1.07) · 2,713 cases | No different | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.962 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.1 · 116 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20 · 316 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 20 · 83 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 7.1 · 298 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 27.3 · 269 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.4 · 283 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.7 · 150 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.9 (9.7 to 17.1) · 529 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.6 to 1.3) · 45 cases | No different | Jan 2024 – Dec 2024 |
What patients said (610 patients answered, 13% of those asked)
| Cleanliness | 3 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 2 |
| Quietness | 2 |
| Recommend hospital | 2 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 70% |
| Doctors "always" communicated well | 72% |
| Staff "always" explained | 53% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 83% |
| Doctors "always" explained things so they could understand | 67% |
| Doctors "always" listened carefully | 70% |
| Doctors "always" treated them with courtesy and respect | 80% |
| Patients who gave a rating of "9" or "10" (high) | 60% |
| Staff "always" explained new medications | 67% |
| Nurses "always" explained things so they could understand | 64% |
| Nurses "always" listened carefully | 66% |
| Nurses "always" treated them with courtesy and respect | 78% |
| "Always" quiet at night | 44% |
| "YES", patients would definitely recommend the hospital | 60% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
See every measure and the patient survey for Sutter Medical Center, Sacramento
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 0 better, 9 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.9 (12 to 15.9) · 992 cases | Worse | Jan 2024 – Dec 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.066 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.335 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.215 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.46 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.253 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.12 (0.29 to 1.94) · 2,408 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.99 (0.78 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.68 (126.66 to 206.71) · 180 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.4 · 292 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.7 · 143 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.2 · 359 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.8 · 543 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.9 · 425 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.4 · 441 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 5,216 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.11 (0 to 0.29) · 9,948 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.1 to 0.45) · 10,968 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.04 (1.53 to 4.56) · 3,983 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.33 (0.2 to 2.46) · 2,033 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.78 (1.69 to 3.87) · 3,594 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.79 (6.29 to 13.29) · 2,100 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.62 (4.04 to 9.2) · 2,018 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.63 (0.29 to 2.98) · 867 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.54 (0.07 to 1.01) · 8,613 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.3 · 294 cases | None | Apr 2023 – Mar 2025 |
| SSI - Abdominal HysterectomyInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 598 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.9 · 924 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 8.5 · 488 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -18.3 · 638 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 24.4 · 443 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.7 · 600 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.9 (3.9 to 6.1) · 992 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 298 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9 · 249 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 250 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.3 (8.7 to 14.6) · 1,326 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.3) · 934 cases | No different | Jan 2024 – Dec 2024 |
What patients said (700 patients answered, 20% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 84% |
| Doctors "always" explained things so they could understand | 75% |
| Doctors "always" listened carefully | 77% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 49% |
| "YES", patients would definitely recommend the hospital | 79% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
See every measure and the patient survey for Sutter Roseville Medical Center
Behind the star rating — Deaths: 2 better, 5 the same, 0 worse of 7 measures. Safety: 5 better, 1 the same, 1 worse of 7 measures. Readmissions: 2 better, 7 the same, 1 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Pressure ulcer rateComplications and deaths | 0.08 (0 to 0.56) · 12,400 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.069 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.262 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.128 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.357 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.33 (0.49 to 2.17) · 2,916 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.9 (0.63 to 1.17) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 147.2 (107.33 to 187.07) · 191 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 7.9 · 250 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.7 · 484 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.4 · 839 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.3 · 1,027 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10 · 656 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.8 · 6,822 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.25 (0.08 to 0.42) · 14,300 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.23 (0.06 to 0.41) · 14,490 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.43 (2.77 to 6.08) · 3,117 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.38 (0 to 2.95) · 938 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.06 (0.76 to 3.36) · 2,944 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.03 (2.8 to 15.25) · 840 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.43 (3.11 to 9.75) · 899 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.73 (0.34 to 3.11) · 819 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.4 · 35 cases | None | Apr 2023 – Mar 2025 |
| SSI - Colon SurgeryInfections | 0.41 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.9 · 527 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.6 · 1,094 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -16.6 · 443 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -11 · 961 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -8 · 1,064 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.1 · 1,293 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.5 (3.5 to 8.7) · 35 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.2 (6.9 to 14.9) · 35 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 36 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 18.5 · 310 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.8 to 17.9) · 116 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.7 to 1) · 1,600 cases | No different | Jan 2024 – Dec 2024 |
What patients said (537 patients answered, 24% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 74% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 62% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 77% |
| Staff "always" explained new medications | 77% |
| Nurses "always" explained things so they could understand | 78% |
| Nurses "always" listened carefully | 75% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 52% |
| "YES", patients would definitely recommend the hospital | 79% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$72,204
Medicare paid this office $72,204 for 321 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 74 | $24,375 | $104 |
| Long return visit (40+ min) | 84 | $13,960 | $122 |
| Return visit (30+ min) | 117 | $11,412 | $80 |
| Return visit (30+ min) | 66 | $7,135 | $103 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 40 | $6,165 | $154 |
See all 8 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 74 | $24,375 | $104 |
| Long return visit (40+ min) | 84 | $13,960 | $122 |
| Return visit (30+ min) | 117 | $11,412 | $80 |
| Return visit (30+ min) | 66 | $7,135 | $103 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 40 | $6,165 | $154 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 131 | $2,574 | $15 |
| Long return visit (40+ min) | 13 | $1,770 | $136 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 48 | $666 | $14 |
Who their Medicare patients are
321 Original Medicare patients in 2024. Average age 60 · Under 65 53% · Women 39% · Also on Medicaid 57% · Health risk score 5.26. Sicker patients than 9 in 10 peers; the typical internal medicine clinician is at 1.76.
Conditions among them: High blood pressure 75% · Chronic kidney disease 75% · Diabetes 64% · Coronary heart disease 44% · Heart failure 29% · Depression 23% · Atrial fibrillation 21% · COPD 11% · Cancer 8% · Stroke 7%.
The office billed $288,357, Medicare allowed $93,722 and paid $72,204; for 882 services of 14 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 321 | 882 | 60 | 5.26 | $288,357 | $72,204 |
| 2023 | 267 | 537 | 60 | 5.24 | $214,106 | $57,713 |
| 2022 | 340 | 646 | 61 | 4.55 | $247,180 | $64,257 |
| 2021 | 332 | 691 | 60 | 4.96 | $258,942 | $70,536 |
| 2020 | 324 | 668 | 60 | 5.19 | $269,374 | $63,350 |
| 2019 | 314 | 603 | 60 | 5.67 | $267,613 | $60,144 |
| 2018 | 356 | 708 | 60 | 4.80 | $295,327 | $65,055 |
| 2017 | 374 | 850 | 60 | 4.73 | $348,772 | $78,250 |
| 2016 | 347 | 867 | 58 | 5.11 | $365,212 | $82,480 |
| 2015 | 358 | 735 | 59 | 4.71 | $291,117 | $66,835 |
| 2014 | 416 | 874 | 59 | 4.89 | $364,548 | $85,044 |
| 2013 | 401 | 912 | 58 | 4.94 | $350,235 | $86,931 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 5 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 70 | $22,937 | $108 |
| Return visit (30+ min) | 106 | $10,861 | $88 |
| Long return visit (40+ min) | 51 | $8,108 | $131 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 36 | $6,451 | $157 |
| Return visit (30+ min) | 48 | $4,767 | $95 |
2022: 8 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 78 | $21,192 | $91 |
| Return visit (30+ min) | 102 | $11,141 | $100 |
| Long return visit (40+ min) | 63 | $9,778 | $124 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 44 | $7,752 | $172 |
| Return visit (30+ min) | 90 | $7,384 | $75 |
| Long return visit (40+ min) | 19 | $2,747 | $137 |
| Telephone medical discussion with physician, 21-30 minutes | 14 | $1,341 | $89 |
| Telephone medical discussion with physician, 21-30 minutes | 14 | $1,222 | $81 |
2021: 8 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 87 | $24,886 | $94 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 58 | $10,367 | $173 |
| Return visit (30+ min) | 93 | $10,065 | $102 |
| Long return visit (40+ min) | 76 | $9,587 | $117 |
| Return visit (30+ min) | 98 | $8,976 | $79 |
| Telephone medical discussion with physician, 21-30 minutes | 25 | $2,095 | $84 |
| Telephone medical discussion with physician, 21-30 minutes | 18 | $1,871 | $98 |
| Long return visit (40+ min) | 12 | $1,747 | $146 |
2020: 9 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 84 | $23,160 | $96 |
| Long return visit (40+ min) | 75 | $9,230 | $100 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 46 | $8,951 | $186 |
| Return visit (30+ min) | 93 | $6,935 | $67 |
| Return visit (30+ min) | 68 | $6,229 | $90 |
| Long return visit (40+ min) | 14 | $1,761 | $110 |
| Telephone medical discussion with physician, 21-30 minutes | 21 | $1,740 | $73 |
| Telephone medical discussion with physician, 21-30 minutes | 16 | $1,706 | $95 |
| Telephone medical discussion with physician, 11-20 minutes | 12 | $556 | $46 |
2019: 10 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 72 | $18,929 | $94 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 49 | $9,664 | $182 |
| Return visit (30+ min) | 99 | $7,637 | $70 |
| Return visit (30+ min) | 68 | $5,575 | $77 |
| New patient visit (60+ min) | 31 | $5,310 | $171 |
| Long return visit (40+ min) | 50 | $4,915 | $96 |
| Extended office or other outpatient service, first hour | 20 | $2,158 | $108 |
| New patient visit (60+ min) | 14 | $2,093 | $150 |
| Dialysis procedure including 1 evaluation | 11 | $1,496 | $79 |
| Hemodialysis procedure with physician evaluation | 12 | $989 | $66 |
2018: 7 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 91 | $24,833 | $90 |
| Return visit (30+ min) | 127 | $9,592 | $65 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 49 | $8,862 | $174 |
| Return visit (30+ min) | 92 | $8,044 | $86 |
| Long return visit (40+ min) | 36 | $3,639 | $93 |
| New patient visit (60+ min) | 20 | $3,261 | $163 |
| Dialysis procedure including 1 evaluation | 14 | $3,070 | $75 |
2017: 9 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 100 | $33,643 | $90 |
| Return visit (30+ min) | 129 | $11,036 | $82 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 57 | $10,702 | $175 |
| Return visit (30+ min) | 94 | $6,190 | $61 |
| Dialysis procedure including 1 evaluation | 17 | $4,452 | $75 |
| Long return visit (40+ min) | 43 | $4,049 | $94 |
| New patient visit (60+ min) | 20 | $2,947 | $147 |
| Hemodialysis procedure with physician evaluation | 20 | $2,054 | $62 |
| Extended office or other outpatient service, first hour | 12 | $1,272 | $106 |
2016: 9 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 118 | $35,740 | $92 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 78 | $15,608 | $177 |
| Return visit (30+ min) | 94 | $8,328 | $83 |
| Return visit (30+ min) | 98 | $7,585 | $65 |
| Long return visit (40+ min) | 55 | $5,792 | $97 |
| Dialysis procedure including 1 evaluation | 14 | $3,088 | $77 |
| New patient visit (60+ min) | 22 | $2,564 | $117 |
| Hemodialysis procedure with physician evaluation | 17 | $1,655 | $64 |
| Extended office or other outpatient service, first hour | 12 | $1,050 | $81 |
2015: 7 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 93 | $28,263 | $93 |
| Return visit (30+ min) | 132 | $12,378 | $85 |
| Return visit (30+ min) | 108 | $8,435 | $66 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 43 | $7,933 | $180 |
| Long return visit (40+ min) | 31 | $3,167 | $99 |
| Dialysis procedure including 1 evaluation | 12 | $2,099 | $78 |
| Hemodialysis procedure with physician evaluation | 14 | $1,219 | $64 |
2014: 8 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 112 | $31,907 | $93 |
| Return visit (30+ min) | 141 | $12,698 | $84 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 60 | $11,924 | $181 |
| New patient visit (60+ min) | 51 | $8,435 | $165 |
| Return visit (30+ min) | 100 | $7,134 | $65 |
| Dialysis procedure including 1 evaluation | 16 | $3,917 | $78 |
| Long return visit (40+ min) | 35 | $3,295 | $94 |
| Hemodialysis procedure with physician evaluation | 19 | $1,812 | $65 |
2013: 7 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 108 | $36,555 | $90 |
| Return visit (30+ min) | 237 | $24,773 | $90 |
| New patient visit (60+ min) | 46 | $7,624 | $166 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 38 | $6,862 | $176 |
| Dialysis procedure including 1 evaluation | 22 | $3,315 | $77 |
| Hemodialysis procedure with physician evaluation | 18 | $3,156 | $63 |
| Long return visit (40+ min) | 16 | $1,938 | $121 |
Medicaid work
$2,357 in 2024
Medicaid paid $2,357 for 54 billed services this clinician did in 2024, up to 15 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 42 | $1,725 |
| Long return visit (40+ min) | 12 | $631 |
| 2024 | 54 | 2 | 15 | $2,357 |
| 2023 | 144 | 2 | 21 | $4,952 |
| 2022 | 131 | 3 | 30 | $6,313 |
| 2021 | 112 | 3 | 14 | $4,852 |
| 2020 | 144 | 3 | 26 | $5,997 |
| 2019 | 73 | 1 | 21 | $2,142 |
| 2018 | 58 | 1 | 24 | $2,251 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 104 | $3,019 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 40 | $1,933 |
2022
| Return visit (30+ min) | 91 | $3,720 |
| OFFICE/OP CONSLTJ NEW/EST PT HIGH MDM 55 MINUTES | 14 | $1,352 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 26 | $1,241 |
2021
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 47 | $2,107 |
| Long return visit (40+ min) | 24 | $1,458 |
| Return visit (30+ min) | 41 | $1,287 |
2020
| Return visit (30+ min) | 91 | $3,295 |
| Long return visit (40+ min) | 28 | $1,408 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 25 | $1,294 |
2019
| Return visit (30+ min) | 73 | $2,142 |
2018
| Return visit (30+ min) | 58 | $2,251 |
Drugs they prescribed that Part D paid
$200,541
Pharmacies billed $200,541 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 922) in 2024. At or below the middle of the specialty; the typical internal medicine clinician is at 1%.
827 generic and fewer than 11 brand-name prescriptions · $200,541 in drug cost · 80 antibiotic prescriptions to 48 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Nulojix | 26 | $53,111 | $2,043 |
| Veltassa | 13 | $12,387 | $953 |
| Tacrolimus | 84 | $11,167 | $133 |
| Cinacalcet | 16 | $6,367 | $398 |
| Mycophenolic Acid | 15 | $5,745 | $383 |
See all 18 drugs
| Nulojix | 26 | $53,111 | $2,043 |
| Veltassa | 13 | $12,387 | $953 |
| Tacrolimus | 84 | $11,167 | $133 |
| Cinacalcet | 16 | $6,367 | $398 |
| Mycophenolic Acid | 15 | $5,745 | $383 |
| Everolimus | 23 | $5,349 | $233 |
| Valganciclovir | 47 | $3,471 | $74 |
| Mycophenolate Mofetil | 36 | $2,843 | $79 |
| Clotrimazole | 15 | $2,341 | $156 |
| Prednisone | 228 | $1,321 | $6 |
| Carvedilol | 22 | $343 | $16 |
| Pantoprazole | 42 | $214 | $5 |
| Amlodipine Besylate | 42 | $213 | $5 |
| Losartan | 28 | $185 | $7 |
| Sulfamethoxazole-Trimethoprim | 38 | $165 | $4 |
| Metoprolol | 17 | $85 | $5 |
| Cephalexin | 11 | $36 | $3 |
| Furosemide | 14 | $36 | $3 |
Year by year
| 2024 | 922 | 224 | 0% (0) | None | $200,541 |
| 2023 | 842 | 218 | 0% (0) | 6% | $220,375 |
| 2022 | 1,035 | 244 | 0% (0) | 8% | $342,965 |
| 2021 | 1,599 | 318 | 0% (0) | 3% | $178,941 |
| 2020 | 1,713 | 316 | 0% (0) | 7% | $252,711 |
| 2019 | 1,828 | 313 | None | 6% | $254,416 |
| 2018 | 1,745 | 269 | 1% (13) | 5% | $154,941 |
| 2017 | 2,092 | 273 | 1% (17) | 7% | $268,852 |
| 2016 | 3,172 | 285 | 1% (29) | 11% | $586,949 |
| 2015 | 2,792 | 268 | 1% (21) | 12% | $516,859 |
| 2014 | 2,561 | 247 | 1% (26) | 14% | $491,108 |
| 2013 | 2,409 | 257 | 1% (23) | 19% | $410,871 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 20 drugs
| Cinacalcet | 27 | $40,507 | $1,500 |
| Nulojix | 15 | $30,159 | $2,011 |
| Tacrolimus | 107 | $29,791 | $278 |
| Mycophenolic Acid | 17 | $10,200 | $600 |
| Mycophenolate Mofetil | 67 | $10,028 | $150 |
| Valganciclovir | 50 | $8,870 | $177 |
| Clotrimazole | 23 | $4,545 | $198 |
| Prednisone | 147 | $1,246 | $8 |
| Nitrofurantoin | 11 | $1,062 | $97 |
| Azathioprine | 16 | $1,014 | $63 |
| Nano 2nd Gen Pen Needle | 13 | $862 | $66 |
| Losartan | 14 | $665 | $47 |
| Sulfamethoxazole-Trimethoprim | 54 | $623 | $12 |
| Pantoprazole | 48 | $453 | $9 |
| Amlodipine Besylate | 29 | $443 | $15 |
| Hydralazine | 15 | $390 | $26 |
| Metoprolol | 16 | $160 | $10 |
| Carvedilol | 11 | $138 | $13 |
| Atorvastatin | 13 | $87 | $7 |
| Furosemide | 12 | $80 | $7 |
2022: 23 drugs
| Gammagard Liquid | Immune globulin | 11 | $104,228 | $9,475 |
| Nulojix | None | 23 | $48,009 | $2,087 |
| Tacrolimus | None | 95 | $35,909 | $378 |
| Cinacalcet | None | 32 | $29,548 | $923 |
| Valganciclovir | None | 45 | $23,045 | $512 |
| Veltassa | None | 16 | $16,037 | $1,002 |
| Mycophenolate Mofetil | None | 77 | $7,831 | $102 |
| Mycophenolic Acid | None | 19 | $7,021 | $370 |
| Clotrimazole | None | 24 | $4,200 | $175 |
| Fluconazole | None | 24 | $2,043 | $85 |
| Nano 2nd Gen Pen Needle | None | 23 | $1,637 | $71 |
| Prednisone | None | 202 | $1,531 | $8 |
| Nitrofurantoin | None | 17 | $1,447 | $85 |
| Amlodipine Besylate | None | 55 | $612 | $11 |
| Carvedilol | None | 32 | $483 | $15 |
| Pantoprazole | None | 49 | $449 | $9 |
| Losartan | None | 17 | $404 | $24 |
| Metoprolol | None | 30 | $347 | $12 |
| Sulfamethoxazole-Trimethoprim | None | 39 | $346 | $9 |
| Hydralazine | None | 18 | $288 | $16 |
| Clonidine | None | 12 | $240 | $20 |
| Tamsulosin | None | 11 | $97 | $9 |
| Cephalexin | None | 13 | $78 | $6 |
2021: 25 drugs
| Tacrolimus | 167 | $59,599 | $357 |
| Valganciclovir | 56 | $23,130 | $413 |
| Mycophenolic Acid | 46 | $16,911 | $368 |
| Cinacalcet | 22 | $14,133 | $642 |
| Mycophenolate Mofetil | 96 | $8,342 | $87 |
| Clotrimazole | 26 | $3,543 | $136 |
| Prednisone | 257 | $2,062 | $8 |
| Nitrofurantoin | 19 | $1,903 | $100 |
| Fluconazole | 29 | $1,899 | $65 |
| Dipyridamole | 12 | $1,842 | $154 |
| Nano 2nd Gen Pen Needle | 23 | $1,549 | $67 |
| Nifedipine Er | 25 | $1,468 | $59 |
| Labetalol | 23 | $1,195 | $52 |
| Carvedilol | 100 | $1,073 | $11 |
| Pantoprazole | 81 | $922 | $11 |
| Amlodipine Besylate | 132 | $905 | $7 |
| Hydralazine | 47 | $628 | $13 |
| Calcitriol | 14 | $610 | $44 |
| Sulfamethoxazole-Trimethoprim | 64 | $527 | $8 |
| Metoprolol | 74 | $505 | $7 |
| Metoprolol | 19 | $314 | $17 |
| Tamsulosin | 13 | $289 | $22 |
| Losartan | 20 | $286 | $14 |
| Clonidine | 16 | $228 | $14 |
| Furosemide | 18 | $82 | $5 |
2020: 32 drugs
| Cinacalcet | 50 | $63,904 | $1,278 |
| Tacrolimus | 125 | $30,107 | $241 |
| Valganciclovir | 50 | $27,448 | $549 |
| Vemlidy | 15 | $18,331 | $1,222 |
| Mycophenolate Mofetil | 80 | $9,386 | $117 |
| Novolog Flexpen | 15 | $8,773 | $585 |
| Mycophenolic Acid | 25 | $8,587 | $343 |
| Januvia | 13 | $6,349 | $488 |
| Clotrimazole | 24 | $4,442 | $185 |
| Nitrofurantoin | 31 | $2,022 | $65 |
| Prednisone | 225 | $1,885 | $8 |
| Ultra-Fine Nano Pen Needle | 25 | $1,503 | $60 |
| Nifedipine Er | 14 | $1,257 | $90 |
| Hydralazine | 50 | $1,097 | $22 |
| Calcitriol | 15 | $1,015 | $68 |
| Amlodipine Besylate | 162 | $966 | $6 |
| Azathioprine | 14 | $907 | $65 |
| Pantoprazole | 88 | $809 | $9 |
| Carvedilol | 99 | $788 | $8 |
| Fluconazole | 13 | $773 | $59 |
| Nano 2nd Gen Pen Needle | 13 | $761 | $59 |
| Tamsulosin | 37 | $518 | $14 |
| Metoprolol | 70 | $434 | $6 |
| Clonidine | 33 | $316 | $10 |
| Atorvastatin | 32 | $293 | $9 |
| Sulfamethoxazole-Trimethoprim | 45 | $285 | $6 |
| Losartan | 30 | $285 | $10 |
| Omeprazole | 16 | $147 | $9 |
| Ciprofloxacin | 18 | $132 | $7 |
| Furosemide | 37 | $131 | $4 |
| Isosorbide Mononitrate Er | 13 | $114 | $9 |
| Lisinopril | 23 | $82 | $4 |
2019: 31 drugs
| Valganciclovir | 100 | $74,122 | $741 |
| Sensipar | 28 | $36,780 | $1,314 |
| Cinacalcet | 19 | $24,683 | $1,299 |
| Tacrolimus | 86 | $16,997 | $198 |
| Mycophenolic Acid | 13 | $9,448 | $727 |
| Novolog Flexpen | 13 | $7,390 | $568 |
| Clotrimazole | 44 | $7,042 | $160 |
| Mycophenolate Mofetil | 69 | $6,226 | $90 |
| Nifedipine Er | 31 | $1,713 | $55 |
| Pantoprazole | 125 | $1,642 | $13 |
| Prednisone | 189 | $1,632 | $9 |
| Ultra-Fine Nano Pen Needle | 30 | $1,520 | $51 |
| Calcitriol | 19 | $1,176 | $62 |
| Bethanechol Chloride | 12 | $1,139 | $95 |
| Metoprolol | 102 | $964 | $9 |
| Amlodipine Besylate | 196 | $919 | $5 |
| Fluconazole | 15 | $896 | $60 |
| Tamsulosin | 66 | $877 | $13 |
| Sulfamethoxazole-Trimethoprim | 92 | $824 | $9 |
| Azathioprine | 17 | $733 | $43 |
| Atorvastatin | 58 | $572 | $10 |
| Carvedilol | 78 | $525 | $7 |
| Metoprolol | 14 | $404 | $29 |
| Clonidine | 42 | $275 | $7 |
| Hydralazine | 25 | $246 | $10 |
| Furosemide | 32 | $216 | $7 |
| Omeprazole | 14 | $187 | $13 |
| Finasteride | 11 | $132 | $12 |
| Warfarin | 15 | $118 | $8 |
| Lisinopril | 30 | $117 | $4 |
| Metoclopramide | 13 | $81 | $6 |
2018: 35 drugs
| Valganciclovir | 54 | $48,823 | $904 |
| Sensipar | 19 | $20,252 | $1,066 |
| Tacrolimus | 59 | $11,298 | $191 |
| Novolog Flexpen | 16 | $8,779 | $549 |
| Lantus Solostar | 14 | $5,545 | $396 |
| Clotrimazole | 35 | $4,796 | $137 |
| Mycophenolate Mofetil | 27 | $4,066 | $151 |
| Clonidine | 21 | $2,512 | $120 |
| Prednisone | 205 | $1,669 | $8 |
| Calcitriol | 33 | $1,493 | $45 |
| Bethanechol Chloride | 13 | $1,167 | $90 |
| Midodrine | 18 | $1,102 | $61 |
| Amlodipine Besylate | 188 | $1,079 | $6 |
| Tamsulosin | 48 | $1,004 | $21 |
| Labetalol | 20 | $999 | $50 |
| Nifedipine Er | 22 | $855 | $39 |
| Ultra-Fine Nano Pen Needle | 18 | $834 | $46 |
| Atorvastatin | 84 | $739 | $9 |
| Hydralazine | 55 | $718 | $13 |
| Azathioprine | 13 | $679 | $52 |
| Pantoprazole | 77 | $673 | $9 |
| Metoprolol | 108 | $667 | $6 |
| Metoprolol | 20 | $582 | $29 |
| Carvedilol | 91 | $466 | $5 |
| Sulfamethoxazole-Trimethoprim | 58 | $417 | $7 |
| Omeprazole | 35 | $399 | $11 |
| Unifine Pentips | 13 | $306 | $24 |
| Rosuvastatin | 12 | $291 | $24 |
| Simvastatin | 35 | $253 | $7 |
| Losartan | 26 | $251 | $10 |
| Clonidine | 43 | $241 | $6 |
| Pioglitazone | 12 | $116 | $10 |
| Warfarin | 13 | $115 | $9 |
| Furosemide | 22 | $104 | $5 |
| Hydrocodone-Acetaminophen | 12 | $102 | $8 |
2017: 33 drugs
| Valganciclovir | 56 | $78,634 | $1,404 |
| Sensipar | 24 | $58,503 | $2,438 |
| Novolog Flexpen | 25 | $16,630 | $665 |
| Tacrolimus | 80 | $13,585 | $170 |
| Mycophenolate Mofetil | 42 | $6,951 | $166 |
| Lantus Solostar | 12 | $4,601 | $383 |
| Clotrimazole | 40 | $3,757 | $94 |
| Prednisone | 249 | $2,378 | $10 |
| Clonidine | 12 | $1,998 | $166 |
| Calcitriol | 43 | $1,443 | $34 |
| Tamsulosin | 59 | $1,336 | $23 |
| Azathioprine | 22 | $1,331 | $60 |
| Bethanechol Chloride | 11 | $1,214 | $110 |
| Pantoprazole | 97 | $1,023 | $11 |
| Atorvastatin | 117 | $992 | $8 |
| Metoprolol | 197 | $974 | $5 |
| Amlodipine Besylate | 210 | $965 | $5 |
| Metoprolol | 35 | $888 | $25 |
| Hydralazine | 58 | $819 | $14 |
| Unifine Pentips | 35 | $797 | $23 |
| Labetalol | 18 | $797 | $44 |
| Omeprazole | 48 | $619 | $13 |
| Clonidine | 81 | $510 | $6 |
| Sulfamethoxazole-Trimethoprim | 61 | $427 | $7 |
| Minoxidil | 12 | $386 | $32 |
| Ondansetron Odt | 14 | $372 | $27 |
| Simvastatin | 43 | $323 | $8 |
| Carvedilol | 71 | $284 | $4 |
| Hydrocodone-Acetaminophen | 16 | $133 | $8 |
| Lisinopril | 22 | $110 | $5 |
| Clopidogrel | 14 | $63 | $4 |
| Isoniazid | 11 | $63 | $6 |
| Furosemide | 12 | $19 | $2 |
2016: 47 drugs
| Valganciclovir | 129 | $194,594 | $1,508 |
| Sensipar | 21 | $32,529 | $1,549 |
| Tacrolimus | 134 | $28,874 | $215 |
| Novolog Flexpen | 43 | $21,703 | $505 |
| Lantus Solostar | 54 | $20,391 | $378 |
| Nexium | 63 | $19,973 | $317 |
| Humalog Kwikpen U-100 | 37 | $19,650 | $531 |
| Mycophenolic Acid | 18 | $10,294 | $572 |
| Mycophenolate Mofetil | 51 | $9,536 | $187 |
| Clotrimazole | 70 | $8,614 | $123 |
| Crestor | 26 | $6,524 | $251 |
| Tamsulosin | 84 | $3,084 | $37 |
| Clonidine | 16 | $3,019 | $189 |
| Prednisone | 266 | $2,455 | $9 |
| Pantoprazole | 242 | $2,266 | $9 |
| Amlodipine Besylate | 325 | $1,806 | $6 |
| Bd Ultra-Fine Pen Needle | 35 | $1,579 | $45 |
| Atorvastatin | 106 | $1,476 | $14 |
| Metoprolol | 222 | $1,427 | $6 |
| Labetalol | 31 | $1,415 | $46 |
| Hydralazine | 65 | $1,267 | $19 |
| Metoprolol | 29 | $1,195 | $41 |
| Omeprazole | 117 | $1,103 | $9 |
| Sulfamethoxazole-Trimethoprim | 114 | $970 | $9 |
| Calcitriol | 29 | $954 | $33 |
| Duloxetine | 13 | $952 | $73 |
| Potassium Chloride | 20 | $822 | $41 |
| Fluconazole | 13 | $800 | $62 |
| Nitrofurantoin | 13 | $670 | $52 |
| Bethanechol Chloride | 14 | $665 | $47 |
| Nifedipine Er | 29 | $661 | $23 |
| Carvedilol | 121 | $651 | $5 |
| Clonidine | 62 | $643 | $10 |
| Minoxidil | 21 | $528 | $25 |
| Pen Needles | 29 | $475 | $16 |
| Unifine Pentips | 21 | $448 | $21 |
| Simvastatin | 62 | $340 | $5 |
| Levothyroxine | 18 | $323 | $18 |
| Hydrocodone-Acetaminophen | 24 | $283 | $12 |
| Azathioprine | 11 | $282 | $26 |
| Dipyridamole | 12 | $257 | $21 |
| Clopidogrel | 39 | $237 | $6 |
| Lisinopril | 24 | $132 | $6 |
| Pioglitazone | 12 | $126 | $11 |
| Pravastatin | 13 | $120 | $9 |
| Gabapentin | 12 | $78 | $6 |
| Finasteride | 12 | $70 | $6 |
2015: 51 drugs
| Valganciclovir | 65 | $100,106 | $1,540 |
| Xeljanz | 11 | $59,124 | $5,375 |
| Sensipar | 33 | $38,876 | $1,178 |
| Mycophenolic Acid | 31 | $22,206 | $716 |
| Tacrolimus | 73 | $21,076 | $289 |
| Lantus Solostar | 37 | $14,007 | $379 |
| Nexium | 43 | $12,979 | $302 |
| Humalog Kwikpen U-100 | 29 | $12,407 | $428 |
| Procrit | 13 | $11,499 | $885 |
| Humalog | 13 | $10,135 | $780 |
| Novolog Flexpen | 19 | $9,130 | $481 |
| Clotrimazole | 52 | $8,383 | $161 |
| Mycophenolate Mofetil | 35 | $3,864 | $110 |
| Crestor | 17 | $3,640 | $214 |
| Tamsulosin | 90 | $2,853 | $32 |
| Pantoprazole | 223 | $2,426 | $11 |
| Labetalol | 49 | $1,979 | $40 |
| Omeprazole | 172 | $1,894 | $11 |
| Amlodipine Besylate | 286 | $1,692 | $6 |
| Prednisone | 208 | $1,657 | $8 |
| Atorvastatin | 109 | $1,490 | $14 |
| Calcitriol | 43 | $1,362 | $32 |
| Metoprolol | 19 | $1,339 | $70 |
| Hydralazine | 71 | $1,260 | $18 |
| Potassium Chloride | 21 | $1,080 | $51 |
| Metoprolol | 173 | $1,068 | $6 |
| Bd Ultra-Fine Pen Needle | 26 | $993 | $38 |
| Valsartan | 18 | $951 | $53 |
| Clonidine | 73 | $674 | $9 |
| Carvedilol | 96 | $635 | $7 |
| Sulfamethoxazole-Trimethoprim | 69 | $602 | $9 |
| Nitrofurantoin | 15 | $555 | $37 |
| Enalapril Maleate | 14 | $482 | $34 |
| Pravastatin | 18 | $433 | $24 |
| Nifedipine Er | 18 | $319 | $18 |
| Pen Needles | 17 | $284 | $17 |
| Azathioprine | 13 | $249 | $19 |
| Losartan | 31 | $238 | $8 |
| Unifine Pentips | 11 | $238 | $22 |
| Levothyroxine | 15 | $228 | $15 |
| Simvastatin | 41 | $180 | $4 |
| Hydrocodone-Acetaminophen | 16 | $174 | $11 |
| Paroxetine | 13 | $166 | $13 |
| Pioglitazone | 14 | $158 | $11 |
| Gabapentin | 14 | $148 | $11 |
| Lisinopril | 24 | $133 | $6 |
| Allopurinol | 17 | $118 | $7 |
| Clopidogrel | 22 | $106 | $5 |
| Finasteride | 13 | $84 | $6 |
| Atenolol | 15 | $74 | $5 |
| Ciprofloxacin | 12 | $59 | $5 |
2014: 42 drugs
| Valcyte | 61 | $167,457 | $2,745 |
| Xeljanz | 12 | $56,155 | $4,680 |
| Sensipar | 36 | $34,614 | $961 |
| Mycophenolic Acid | 34 | $31,404 | $924 |
| Tacrolimus | 60 | $17,119 | $285 |
| Humalog | 28 | $15,042 | $537 |
| Rapamune | 14 | $14,423 | $1,030 |
| Mycophenolate Mofetil | 78 | $10,580 | $136 |
| Viread | 11 | $9,692 | $881 |
| Lantus Solostar | 13 | $5,377 | $414 |
| Clotrimazole | 38 | $4,122 | $108 |
| Pantoprazole | 193 | $2,988 | $15 |
| Omeprazole | 188 | $2,592 | $14 |
| Calcitriol | 45 | $2,298 | $51 |
| Crestor | 12 | $2,288 | $191 |
| Prednisone | 241 | $2,107 | $9 |
| Labetalol | 43 | $1,948 | $45 |
| Atorvastatin | 101 | $1,899 | $19 |
| Tamsulosin | 82 | $1,888 | $23 |
| Amlodipine Besylate | 216 | $1,498 | $7 |
| Nitrofurantoin | 20 | $1,453 | $73 |
| Metoprolol | 167 | $1,366 | $8 |
| Bd Ultra-Fine Pen Needle | 26 | $1,223 | $47 |
| Carvedilol | 101 | $1,186 | $12 |
| Clonidine | 83 | $985 | $12 |
| Fluconazole | 11 | $921 | $84 |
| Nitrofurantoin Mono-Macro | 12 | $859 | $72 |
| Pioglitazone | 22 | $835 | $38 |
| Hydralazine | 41 | $778 | $19 |
| Pravastatin | 16 | $698 | $44 |
| Potassium Chloride | 15 | $640 | $43 |
| Nifedipine Er | 14 | $587 | $42 |
| Losartan | 36 | $451 | $13 |
| Sulfamethoxazole-Trimethoprim | 46 | $419 | $9 |
| Simvastatin | 37 | $297 | $8 |
| Hydrocodone-Acetaminophen | 24 | $219 | $9 |
| Clopidogrel | 23 | $167 | $7 |
| Lisinopril | 20 | $139 | $7 |
| Famotidine | 16 | $105 | $7 |
| Allopurinol | 24 | $95 | $4 |
| Azathioprine | 11 | $85 | $8 |
| Furosemide | 15 | $82 | $5 |
2013: 48 drugs
| Valcyte | 36 | $78,265 | $2,174 |
| Sensipar | 73 | $57,948 | $794 |
| Myfortic | 32 | $34,932 | $1,092 |
| Tacrolimus | 64 | $27,351 | $427 |
| Rapamune | 27 | $25,743 | $953 |
| Hecoria | 25 | $16,127 | $645 |
| Humalog | 39 | $13,746 | $352 |
| Novolog Flexpen | 24 | $8,837 | $368 |
| Lantus Solostar | 28 | $8,598 | $307 |
| Mycophenolate Mofetil | 61 | $7,409 | $121 |
| Nexium | 17 | $6,751 | $397 |
| Lantus | 15 | $6,046 | $403 |
| Omeprazole | 262 | $4,644 | $18 |
| Clotrimazole | 22 | $3,615 | $164 |
| Calcitriol | 51 | $3,339 | $65 |
| Atorvastatin | 67 | $2,792 | $42 |
| Bd Ultra-Fine Pen Needle | 46 | $2,597 | $56 |
| Pantoprazole | 106 | $2,103 | $20 |
| Labetalol | 44 | $2,078 | $47 |
| Amlodipine Besylate | 156 | $1,462 | $9 |
| Tamsulosin | 44 | $1,450 | $33 |
| Nitrofurantoin | 24 | $1,349 | $56 |
| Prednisone | 252 | $1,300 | $5 |
| Metoprolol | 141 | $1,204 | $9 |
| Carvedilol | 59 | $1,010 | $17 |
| Nitrofurantoin Mono-Macro | 14 | $948 | $68 |
| Losartan | 45 | $925 | $21 |
| Clopidogrel | 18 | $872 | $48 |
| Potassium Chloride | 20 | $667 | $33 |
| Simvastatin | 53 | $525 | $10 |
| Clonidine | 32 | $509 | $16 |
| Levetiracetam | 11 | $452 | $41 |
| Pravastatin | 17 | $389 | $23 |
| Nifedipine Er | 11 | $352 | $32 |
| Sulfamethoxazole-Trimethoprim | 32 | $278 | $9 |
| Azathioprine | 12 | $266 | $22 |
| Furosemide | 41 | $246 | $6 |
| Insulin | 12 | $232 | $19 |
| Levothyroxine | 11 | $200 | $18 |
| Hydrocodone-Acetaminophen | 21 | $180 | $9 |
| Enalapril Maleate | 20 | $166 | $8 |
| Atenolol | 20 | $158 | $8 |
| Lisinopril | 12 | $152 | $13 |
| Famotidine | 15 | $146 | $10 |
| Ciprofloxacin | 14 | $128 | $9 |
| Allopurinol | 26 | $102 | $4 |
| Cephalexin | 15 | $71 | $5 |
| Single Use Swab | 19 | $53 | $3 |
Money from drug and device companies
$120 in 2025
| 2025 | 1 | 1 | None | $120 |
| 2024 | 1 | 4 | None | $356 |
| 2023 | 1 | 3 | None | $211 |
| 2022 | 1 | 2 | None | $35 |
| 2019 | 3 | 4 | None | $138 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Sanofi-Aventis U.S. | Thymoglobulin | $120 | 1 payment
|
See the published payment
| Sanofi-Aventis U.S. | Meals · 2025-08-03 | Thymoglobulin | $120 |
See earlier years (2024, 2023, 2022, 2019)
2024: $356
| Sanofi-Aventis U.S. | Thymoglobulin | $356 | 4 payments
|
2023: $211
| Sanofi-Aventis U.S. | None | $211 | 3 payments
|
2022: $35
| Sanofi-Aventis U.S. | Thymoglobulin | $35 | 2 payments
|
2019: $138
| Genzyme | Solid Organ Transplant | $65 | 1 payment
|
| Veloxis Pharmaceuticals | Envarsus | $53 | 2 payments
|
| E.R. Squibb & Sons L.L.C. | Nulojix | $20 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Astellas Pharma Global Development · Astagraf Xl To Understand the Impact of Immunosuppression on De Novo Dsa Development and Chronic Immune Activation in Kidney Transplantation · 2019 | Their institution | $37,808 |
| CSL Behring · A Double-Blind, Randomized-Withdrawal, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Human Plasma-Derived C1-Esterase Inhibitor As Add-on To Standard of Care for the Treatment of Refractory Antibody Mediated Rejection in Adult Renal Transplant Recipients · 2020 | Their institution | $31,470 |
| CSL Behring · A Pivotal Phase 3 Trial To Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody-Mediated Rejection in Kidney Transplant Recipients · 2025 | Their institution | $20,733 |
| E.R. Squibb & Sons, L.L.C. · Evaluation of Acute Rejection Rates in De Novo Renal Transplant Recipients Following Thymoglobulin Induction, Cni-Free, Nulojix Belatacept-Based Immunosuppression · 2019 | Their institution | $13,742 |
| E.R. Squibb & Sons, L.L.C. · Evaluation of the Benefits and Risks in Maintenance Renal Transplant Recipients Following Conversion To Nulojix (Belatacept)-Based Immunosuppression · 2020 | Their institution | $6,355 |
| Astellas Pharma Global Development · Astagraf Xl To Understand the Impact of Immunosuppression on De Novo Dsa Development and Chronic Immune Activation in Kidney Transplantation · 2020 | Their institution | $6,211 |
| CSL Behring · Efficacy and Safety of Human Plasma-Derived C1-Esterase Inhibitor As Add-on To Standard of Care for the Treatment of Refractory Antibody Mediated Rejection Amr in Adult Renal Transplant Recipients · 2019 | Their institution | $3,656 |
| CSL Behring · A Pivotal Phase 3 Trial To Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody-Mediated Rejection in Kidney Transplant Recipients · 2022 | Their institution | $2,910 |
| CSL Behring · A Pivotal Phase 3 Trial To Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody-Mediated Rejection in Kidney Transplant Recipients · 2023 | Their institution | $1,592 |
| CSL Behring · A Pivotal Phase 3 Trial To Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody-Mediated Rejection in Kidney Transplant Recipients · 2024 | Their institution | $1,166 |
Professional record
- NPI
- 1417974247
- Licence
- CA C51237California C51237: Current · expires 2027-04-30
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RN0300X (207RN0300X)
- Mailing address
- Po Box 254947, Sacramento, CA, 95865
- NPI first listed
- 2006-07-16
- NPI last updated
- 2013-03-01
This is when the NPI record was last certified, not a medical board exam.